Allogene Therapeutics, Inc.
NASDAQ:ALLO
1.11 (USD) • At close May 21, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.022 | 0.095 | 0.156 | 114.089 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 11.541 | 5.027 | 1.5 | 0 |
| Gross Profit
| 0.022 | 0.095 | 0.156 | 114.089 | -11.541 | -5.027 | -1.5 | 0 |
| Gross Profit Ratio
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 192.299 | 242.914 | 256.387 | 220.176 | 192.987 | 144.535 | 151.86 | 0 |
| General & Administrative Expenses
| 65.205 | 71.673 | 79.305 | 74.105 | 65.256 | 57.473 | 40.982 | 0.024 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.022 |
| SG&A
| 65.205 | 71.673 | 79.305 | 74.105 | 65.256 | 57.473 | 40.982 | 0.002 |
| Other Expenses
| 15.717 | 13.245 | 0 | 0 | -1.142 | -0.268 | -21.211 | 0 |
| Operating Expenses
| 273.221 | 327.832 | 335.692 | 294.281 | 258.243 | 202.008 | 192.842 | 0.002 |
| Operating Income
| -273.199 | -327.737 | -335.536 | -180.192 | -258.243 | -202.008 | -192.842 | -0.002 |
| Operating Income Ratio
| -12,418.136 | -3,449.863 | -2,150.872 | -1.579 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 16.052 | 0.472 | -4.878 | -1.859 | 8.022 | 17.083 | -18.78 | -0.022 |
| Income Before Tax
| -257.147 | -327.265 | -340.414 | -182.051 | -250.221 | -184.925 | -211.622 | -0.002 |
| Income Before Tax Ratio
| -11,688.5 | -3,444.895 | -2,182.141 | -1.596 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.443 | 0 | 0 | 0 | -16.75 | -0.331 | -0.117 | -0.024 |
| Net Income
| -257.59 | -327.265 | -340.414 | -182.051 | -233.471 | -184.594 | -211.505 | -0.002 |
| Net Income Ratio
| -11,708.636 | -3,444.895 | -2,182.141 | -1.596 | 0 | 0 | 0 | 0 |
| EPS
| -1.32 | -2.09 | -2.32 | -1.89 | -1.94 | -1.83 | -7.31 | 0 |
| EPS Diluted
| -1.32 | -2.09 | -2.32 | -1.89 | -1.94 | -1.83 | -7.31 | 0 |
| EBITDA
| -243.327 | -313.066 | -321.241 | -169.738 | -250.808 | -179.898 | -206.764 | 0.022 |
| EBITDA Ratio
| -11,060.318 | -3,295.432 | -2,059.237 | -1.488 | 0 | 0 | 0 | 0 |